Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

Study Overview
=================
Brief Summary
-----------------
This was an open-label, randomized, dose-finding study in patients with primary or secondary MF (Dynamic International Prognostic Scoring System [DIPSS] risk score of Intermediate-1 to High-Risk) who were previously treated with ruxolitinib. The study was designed to support a pacritinib dosage selection decision with evaluation of 3 dosages.

Official Title
-----------------
Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

Conditions
-----------------
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post- Essential Thrombocythemia Myelofibrosis

Intervention / Treatment
-----------------
* Drug: Pacritinib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: PMF, PPV-MF, or PET-MF (as defined by Tefferi and Vardiman 2008) DIPSS Intermediate-1, Intermediate -2, or High-risk (Passamonti et al 2010) Prior ruxolitinib treatment with failure to benefit or intolerance as defined by at least one of the following: Treatment for ≥3 months with inadequate efficacy response defined as <10% SVR by MRI or <30% decrease from baseline in spleen length by physical examination or regrowth to these parameters following an initial response; and/or Treatment for ≥28 days complicated by either i. Development of a red blood cell (RBC) transfusion requirement (at least 2 units/month for 2 months) ii. National Cancer Institute (NCI) CTCAE grade ≥3 AEs of thrombocytopenia, anemia, hematoma, and/or hemorrhage while being treated with a dosage of <20 mg BID Palpable splenomegaly ≥5 cm below the lower costal margin (LCM) in the midclavicular line as assessed by physical examination TSS of ≥10 on the MPN-SAF TSS 2.0 or patients with a single symptom score of ≥5 or 2 symptoms of ≥3, including only the symptoms of left upper quadrant pain, bone pain, itching, or night sweats Age ≥18 years old Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 Peripheral blast count of <10% throughout the Screening period Absolute neutrophil count of >500/μL Adequate liver and renal function, defined by liver transaminases (aspartate aminotransferase [AST]/serum glutamic-oxaloacetic transaminase [SGOT] and alanine aminotransferase [ALT]/serum glutamic-pyruvic transaminase [SGPT]), ≤3 × the upper limit of normal (ULN) (AST/ALT ≤5 × ULN, if transaminase elevation is related to MF), direct bilirubin ≤4× ULN, and creatinine ≤2.5 mg/dL Adequate coagulation function, defined by prothrombin time (PT)/international normalized ratio (INR), partial thromboplastin time (PTT), or thrombin time (TT) of ≤1.5 × ULN Left ventricular cardiac ejection fraction of ≥45% by echocardiogram or multigated acquisition (MUGA) scan If fertile, willing to use effective birth control methods during the study Willing to undergo and able to tolerate frequent MRI or CT scan assessments during the study Able to understand and willing to complete symptom assessments using a PRO instrument Provision of informed consent Exclusion Criteria: Life expectancy <6 months Completed allogeneic stem cell transplant (allo-SCT) or are eligible for and willing to complete allo-SCT History of splenectomy or planning to undergo splenectomy Splenic irradiation within the last 6 months Previously treated with pacritinib Patients receiving high-dose ruxolitinib (more than 10 mg BID or 20 mg QD) who cannot tolerate tapering down ruxolitinib to 10 mg BID or less prior to the first dose of pacritinib Treatment with anticoagulation or antiplatelet agents, except for aspirin dosages of ≤100 mg per day, within the last 2 weeks Treatment with a strong CYP3A4 inhibitor or a strong cytochrome P450 inducer within the last 2 weeks Treatment with medications that can prolong the QTc interval within the last 2 weeks Treatment with an experimental therapy within the last 28 days Significant recent bleeding history defined as NCI CTCAE grade ≥2 within the last 3 months, unless precipitated by an inciting event (eg, surgery, trauma, or injury) Any history of CTCAE grade ≥2 non-dysrhythmia cardiac conditions within the last 6 months. Patients with asymptomatic grade 2 non-dysrhythmia cardiac conditions may be considered for inclusion, with the approval of the medical monitor, if stable and unlikely to affect patient safety. New York Heart Association Class II, III, or IV congestive heart failure Any history of CTCAE grade ≥2 cardiac dysrhythmias within the last 6 months. Patients with non-QTc CTCAE grade 2 cardiac dysrhythmias may be considered for inclusion, with the approval of the medical monitor, if the dysrhythmias are stable, asymptomatic, and unlikely to affect patient safety. QTc prolongation >450 ms based on the mean of triplicate ECGs or other factors that increase the risk for QT interval prolongation (eg, heart failure, hypokalemia [defined as serum potassium <3.0 mEq/L that is persistent and refractory to correction], family history of long QT interval syndrome, or concomitant use of medications that may prolong QT interval) Any active gastrointestinal or metabolic condition that could interfere with absorption of oral medication Active or uncontrolled inflammatory or chronic functional bowel disorder such as Crohn's Disease, inflammatory bowel disease, chronic diarrhea, or constipation Other malignancy within the last 3 years, other than curatively treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, organ-confined or treated nonmetastatic prostate cancer with negative prostate-specific antigen, in situ breast carcinoma after complete surgical resection, or superficial transitional cell bladder carcinoma Uncontrolled intercurrent illness, including, but not limited to, ongoing active infection or psychiatric illness or social situation that, in the judgment of the treating physician, would limit compliance with study requirements Known seropositivity for human immunodeficiency virus Known active hepatitis A, B, or C virus infection Women who are pregnant or lactating Concurrent enrollment in another interventional trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Pacritinib 100 mg QD<br> | Drug: Pacritinib<br>* Pacritinib<br>|
| Experimental: Pacritinib 100 mg BID<br> | Drug: Pacritinib<br>* Pacritinib<br>|
| Experimental: Pacritinib 200 mg BID<br> | Drug: Pacritinib<br>* Pacritinib<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Spleen Volume Reduction Response (≥ 35%) | Number of patients achieving a ≥ 35% spleen volume reduction (SVR) as measured by magnetic resonance imaging (MRI, preferred) or computed tomography (CT) scans | From Baseline to Weeks 12 and 24 | 
| Percent Change in Spleen Volume | Percent change from baseline | From Baseline to Weeks 12 and 24 | 
| Total Symptom Score Analysis | Proportion of patients with ≥ 50% reduction in Total Symptom Score from baseline as assessed by the validated PRO instrument MPN-SAF TSS 2.0 | From Baseline to Weeks 12 and 24 | 
| Patient Global Impression Assessment | Number of patients with improvement in PGIA. The Patient Global Impression Assessment questionnaire was completed at the end of Week 12 and end of Week 24. The scores were summarized by treatment group at each visit. | From Baseline to Weeks 12 and 24 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Spleen Length Reduction | Rate of reduction in spleen length from baseline | From Baseline to Weeks 24 | 
| Frequency of RBC's or Platelet Transfusions | Number of patients | At week 24 | 
| Eastern Cooperative Oncology Group Performance Status | 0 = Fully active, able to carry on all pre-disease performance without restriction = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work = Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours = Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours = Completely disabled; cannot carry on any selfcare; totally confined to bed or chair = Dead | At weeks 4, 12, 24, and 30 days post End-of-Treatment visit | 
| Number of Participants With Adverse Events |  | Randomization through 30 days post End-of-Treatment visit |